Monitor for the ESMO poster presentation date and session details (to be announced) for potential stock catalyst. The Phase 2b initiation timeline and any partnership interest following ESMO will be key inflection points. Given the $7M market cap, positive news flow can drive outsized moves, but the abstract acceptance alone does not change the fundamental capital needs.
Price Chart
Executive Summary
Can-Fite announced that positive Phase 2a data for Namodenoson in advanced pancreatic cancer was accepted for poster presentation at ESMO Congress 2026, one of the world's top oncology conferences. The study met its primary safety endpoint and showed durable survival in heavily pre-treated patients, with one second-line patient alive >18 months. This external validation supports the company's plan to advance to a Phase 2b combination study, but no new data or financial metrics were disclosed.
Key Facts
- Abstract accepted for poster at ESMO Congress 2026, a premier oncology conference
- Phase 2a study of Namodenoson in advanced PDAC met primary safety endpoint
- Encouraging survival outcomes with durable disease stabilization in predominantly third-line patients
- One patient receiving Namodenoson as second-line therapy remains alive more than 18 months
- Company planning Phase 2b study evaluating Namodenoson in combination with chemotherapy
Financial Impact
No financial data provided; positive clinical milestone may enhance partnership prospects and support further investment, but no immediate revenue impact for this pre-revenue company.
Risk Factors
- No new clinical data released; abstract acceptance is a formality and data was previously disclosed
- Company has history of losses and requires additional capital to fund operations and Phase 2b trial
- Pancreatic cancer is a highly competitive and difficult indication with high clinical trial failure rates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-079394 |
| Document: ea0298522-6k_canfite.htm | 0001213900-26-079394 |
| Document: 0001213900-26-079394-index-headers.html | 0001213900-26-079394 |
| Document: 0001213900-26-079394-index.html | 0001213900-26-079394 |
| Document: 0001213900-26-079394.txt | 0001213900-26-079394 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.95 | awaiting T+5 | — | $1.72 (−11.79%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.72 (+11.79%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.72 (+11.79%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.72 (+25.22%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.72 (−21.46%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.72 (−26.81%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.72 (−27.12%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.72 (+27.12%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.72 (−27.12%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.72 (−51.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers